Post Covid Guillian-Barre Syndrome

Mohammed Khalid; Tariq Karim

doi:10.51131/IJPCCR/v2i2.6

Article

VIEWS 1958
PDF 485

International Journal of Preclinical and Clinical Research

DOI: 10.51131/IJPCCR/v2i2.6

Year: 2021, Volume: 2, Issue: 2, Pages: 46-47

Case Report

Post Covid Guillian-Barre Syndrome

Mohammed Khalid ^1,*, Tariq Karim ²

1 Specialist Internal Medicine, Amina Hospital, Ajman, United Arab Emirates.

2 Consultant Internal Medicine, Amina Hospital, Ajman, United Arab Emirates.

*Corresponding author email: [email protected]

Received Date:30 April 2021, Accepted Date:17 July 2021, Published Date:24 July 2021

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Guillian-Barre Syndrome (GBS) is a rare complication of COVID-19. We report a case of 41- year-old lady who presented with GBS with variant of multiple cranial neuropathies. Supportive care is important in these patient due to the risk associated with respiratory failure and autonomic dysfunction with potential severe cardiovascular involvement. IV immunoglobulin is as effective as plasmapheresis in the treatment of GBS ⁽¹⁾.

Keywords

Guillian Barre Syndrome (GBS), IV Immunoglobulin, Plasmapheresis

References

Hughes RA, Swan AV, Doorn PAv. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews. 2014. Available from: https://dx.doi.org/10.1002/14651858.cd002063.pub6
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683. Available from: 10.1001/jamaneurol.2020.1127
Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nature Reviews Neurology. 2020;16(11):636–644. Available from: https://dx.doi.org/10.1038/s41582-020-0398-3
Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-BarréSyndrome Associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574. Available from: 10.1056/NEJMc2009191
Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacology & Therapeutics. 2004;102(3):177–193. Available from: https://dx.doi.org/10.1016/j.pharmthera.2004.04.002

Copyright

© 2021 Khalid & Karim. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Published By Basaveshwara Medical College & Hospital, Chitradurga, Karnataka.